cbdMD
Develops cannabinoid wellness, pet CBD, mushroom supplements, and THC beverages.
Something off on this page? Send us feedback.
Profile
Produces hemp-derived cannabinoid wellness products, pet CBD, functional-mushroom supplements, and THC beverages under several brands. Revenue comes from direct e-commerce and wholesale distribution, using a hybrid production model with in-house activity and contract manufacturers.
Builds a consumer-wellness portfolio around hemp-derived cannabinoids, serving human and pet customers through the cbdMD, Bluebird Botanicals, and Paw CBD brands. Products include CBD oils, gummies, capsules, soft gels, topicals, and veterinarian-formulated pet tinctures and chews, alongside ATRx functional-mushroom supplements and Oasis hemp-derived THC social beverages.
Sells primarily through its websites, third-party marketplaces, wholesale team, retailers, specialty health and pet channels, and beverage distributors. The United States is its core market, with Oasis distribution focused in the Southeast and Texas; the company also pursues international distributors. It sets specifications and quality oversight while combining selected internal work with contract manufacturing and independent laboratory testing.
Operates in a fragmented cannabinoid category shaped by federal and state product rules, FDA policy, digital advertising and payment access, distributor acceptance, hemp suppliers, manufacturing partners, and laboratory testing.
Company facts
Key statistics
Year to date −56.1% · Average volume (30d) 166.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q3 FY26 | −$0.03 | −$0.11 | −266.7% | $5.7M | $5.6M | −2.4% | −12.26% |
| May 14, 2026Q2 FY26 | −$0.05 | −$0.08 | −60.0% | $5.3M | $5.6M | +6.6% | −5.32% |
| Feb 17, 2026Q1 FY26 | −$0.06 | −$0.04 | +33.3% | $4.9M | $5.0M | +3.3% | −6.83% |
| Dec 19, 2025Q4 FY25 | −$0.07 | −$0.08 | −8.9% | $4.7M | $4.7M | +0.4% | −9.27% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $4.6M | $4.7M | $5.0M | $5.6M | $5.6M | |
| Gross profit | $3.0M | $2.8M | $2.8M | $3.0M | $3.0M | $3.0M | |
| Operating income | −$485.8K | −$904.7K | −$685.8K | −$286.3K | −$800.8K | −$1.1M | |
| Net income | −$480.8K | −$895.3K | −$680.0K | −$283.1K | −$798.0K | −$1.1M | |
| Diluted EPS | −$0.19 | −$0.21 | −$0.08 | −$0.04 | −$0.08 | −$0.11 | |
| Gross margin | 62.3% | 61.5% | 58.8% | 59.8% | 53.3% | 54.7% | |
| Operating margin | -10.2% | -19.6% | -14.5% | -5.7% | -14.2% | -20.4% |
Fiscal years (4-quarter sums)FY24 $19.5M · FY25 $19.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $2.1M · Total debt $2.2M · Total assets $13.1M · Shareholders' equity $8.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 10.50M · Float 10.20M · 97.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| CRC Investment Fund LP ("CRC LP") | 823.1K | 9.20% | 13G | May 12, 2025 |
| Porter Jeffrey H | 573.5K | 6.40% | 13D | May 8, 2025 |
| Worth Venture Partners, LLC | 184.8K | 1.76% | 13F | May 14, 2026 |
| UBS Group AG | 164.6K | 1.57% | 13F | May 5, 2026 |
| CSS LLC/IL | 137.6K | 1.31% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Direxion Daily CSI China Internet Index Bull 2X ETF
Broad CBD, pet, functional-mushroom, and hemp-THC wellness overlap.
- Laird Superfood
Functional-mushroom supplements and wellness-beverage overlap.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| cbdMD | $0.5000 | −1.90% | $5.2M | — | — | 0.3 | +20.6% |
| Direxion Daily CSI China Internet Index Bull 2X ETF | $21.44 | +0.02% | $161.3M | — | — | — | — |
| Laird Superfood | $3.92 | +2.62% | $43.1M | — | 14.3 | 0.6 | +244.4% |
| Median | — | 14.3 | 0.6 | +244.4% |